Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2022-04-27 Capital/Financing Update
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Proposed issue of securities - LCT 5 pages 27.0KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Living Cell Technologies Limited regarding a proposed issue of securities, specifically options expiring in 2024. It details the number of securities to be issued, the proposed issue date, conditions, and other related information. The content focuses on the issuance of new securities, including placement details and compliance with listing rules. There is no financial performance data, audit information, or management discussion. The document is not a report but an announcement about a capital raising activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2022-04-27 English
Cleansing Notice 2 pages 182.6KB
Capital/Financing Update Classification · 95% confidence The document is a cleansing notice under Section 708AA(2)(f) of the Corporations Act 2001 (Cth) regarding the issue of placement options to sophisticated and wholesale investors. It includes legal references to the Corporations Act and details about the options issued, exercise price, expiry date, and compliance statements. The document is an announcement about a capital raising event (placement options issuance) and does not contain financial statements or detailed financial performance data. It is not a full report but a regulatory announcement related to financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is about 5508 characters, which supports it being an announcement rather than a full report.
2022-04-27 English
LCT signs Research Agreement with UTS 3 pages 171.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited regarding a research agreement with the University of Technology Sydney to produce NTCELL in Australia for the first time. It discusses the advancement of a clinical trial and details about the research collaboration and production plans. There are no financial statements, detailed financial performance data, or regulatory filings such as audit reports or earnings releases. The document is a corporate announcement about a research agreement and clinical trial progress, not a financial report or regulatory filing. It is not a report publication announcement since it does not mention the release or availability of a report. Therefore, the document best fits the category of a general regulatory announcement or compliance document that does not fit into other specific categories, which corresponds to Regulatory Filings (RNS).
2022-03-29 English
Notice of General Meeting/ Proxy Form 19 pages 567.0KB
Proxy Solicitation & Information Statement Classification · 95% confidence The document is an ASX announcement regarding a General Meeting of Shareholders for Living Cell Technologies Limited. It includes a Notice of General Meeting, proxy forms, voting instructions, meeting date and time, and details on how to attend the meeting virtually. The content focuses on informing shareholders about the meeting arrangements and voting procedures rather than presenting financial results or detailed reports. There is no financial data, audit information, or earnings release content. The document is lengthy (15,000 characters) but is clearly a meeting notice and related materials. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings.
2022-03-24 English
Funding Update-LCT Advancing NTCELL with Investor Backing 3 pages 172.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement titled 'Funding Update: LCT Advancing NTCELL With Investor Backing'. It discusses recent fundraising activities including a Placement and Rights Issue, the status of shortfall securities, and current cash position. It does not contain financial statements or detailed financial analysis but rather updates on capital raising and funding status. The document is about financing activities and capital structure changes, not a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (7020 characters) and content confirm it is a substantive announcement rather than a brief notice or report publication announcement.
2022-03-20 English
Investor Presentation 15 pages 615.2KB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and contains detailed information about the company's business, market, leadership, product development, regulatory approval, clinical trials, and project timelines. It includes forward-looking statements, market data, and strategic plans typical of presentations aimed at investors. There are no financial statements or audit details, nor is it a regulatory filing or announcement. The length (8203 characters) and content indicate it is the full presentation document, not just an announcement of a report. Therefore, the document fits the category of an Investor Presentation.
2022-03-09 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.